Gary A. Gintant

AbbVie (United States) — United States

Medicine · Health Sciences

42h-index7.5kcitations148works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac electrophysiology and arrhythmias(106), Ion channel regulation and function(61), Neuroscience and Neural Engineering(32), Cardiac pacing and defibrillation studies(21), ECG Monitoring and Analysis(19)

Publications148 total

Corrigendum to “Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As” [J. Pharmacol. Toxicol. Methods 123 (2023) 107270]
Journal of Pharmacological and Toxicological Methods·2025Open Access
Nonclinical comprehensive exposure response QTc-modeling (NCERT) in telemetry instrumented conscious dogs using automated blood sampling
Journal of Pharmacological and Toxicological Methods·2025
Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As
Journal of Pharmacological and Toxicological Methods·2023· 31 cited
Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute
Journal of Pharmacological and Toxicological Methods·2023· 29 citedOpen Access
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Nav1.7/ Nav1.8 blockers for the treatment of pain
Bioorganic & Medicinal Chemistry·2022· 3 citedOpen Access
The Challenges of Predicting Drug-Induced QTc Prolongation in Humans
Toxicological Sciences·2022· 42 citedOpen Access
Assessing the fidelity of translation of non‐clinical assays: a Pharma perspective
British Journal of Pharmacology·2022· 1 citedOpen Access
Automated blood sampling in canine telemetry studies: Enabling enhanced assessments of cardiovascular liabilities and safety margins
Journal of Pharmacological and Toxicological Methods·2021· 1 cited
Automated blood sampling in canine telemetry studies: Enabling enhanced assessments of cardiovascular liabilities and safety margins
Journal of Pharmacological and Toxicological Methods·2021· 4 citedOpen Access
Automated blood sampling in canine telemetry studies: Enabling enhanced assessments of cardiovascular liabilities and safety margins
Journal of Pharmacological and Toxicological Methods·2021· 5 cited
Gaining Efficiency in Clinical Trials With Cardiac Biomarkers
Journal of the American College of Cardiology·2021· 10 cited
Cardiovascular microphysiological systems (CVMPS) for safety studies – a pharma perspective
Lab on a Chip·2021· 19 cited
Identification of Drug-Induced Multichannel Block and Proarrhythmic Risk in Humans Using Continuous T Vector Velocity Effect Profiles Derived From Surface Electrocardiograms
Frontiers in Physiology·2020· 2 citedOpen Access
Drug-induced QT prolongation: Concordance of preclinical canine model in relation to clinical outcome
Journal of Pharmacological and Toxicological Methods·2020
Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective
Clinical Pharmacology & Therapeutics·2020· 92 citedOpen Access
Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations
Regulatory Toxicology and Pharmacology·2020· 52 citedOpen Access
Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells
Scientific Reports·2020· 3 citedOpen Access
Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs
Journal of Pharmacological and Toxicological Methods·2020· 3 citedOpen Access
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells
Scientific Reports·2020· 59 citedOpen Access
The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectations
Expert Opinion on Drug Discovery·2020· 9 cited
page 1 of 8Next →

Frequent Co-authors

Jennifer Pierson(9), Ruth L. Martin(9), Bryan F. Cox(9), Philip T. Sager(6), Norman Stockbridge(6), David G. Strauss(6), Zhi Su(6), Jean‐Pierre Valentin(5), Bernard Fermini(4), Godfrey L. Smith(4), Yasunari Kanda(4), Khuram W. Chaudhary(4), John Koerner(4), Jeff S. McDermott(4), Ira S. Cohen(4), James T. Limberis(4), Ksenia Blinova(3), Qianyu Dang(3), Liang Guo(3), Hong Shi(3)